NASDAQ:PMN Promis Neurosciences Q3 2026 Earnings Date & Estimates $3.26 -0.16 (-4.55%) As of 12:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Promis Neurosciences is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 12, 2026Conference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Promis Neurosciences in Q3 2026Promis Neurosciences is expected to post earnings of -$1.26 per share. In the same quarter a year earlier Promis Neurosciences reported -$6.00 per share. Promis Neurosciences last reported on August 13, 2026, posting -$1.28 per share and beating the -$1.38 consensus estimate. Promis Neurosciences has beaten the consensus EPS estimate in 3 of its last 7 quarters.Consensus EstimatesConsensus EPS-$1.26Prior-Year EPS-$6.00Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.28 (Beat by +$0.10)EPS Beat Rate3 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Promis Neurosciences Q3 2026 Earnings FAQ When does Promis Neurosciences report Q3 2026 earnings? Promis Neurosciences (NASDAQ:PMN) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Promis Neurosciences' Q3 2026 earnings call? Promis Neurosciences' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Promis Neurosciences? Analysts expect Promis Neurosciences to post earnings of -$1.26 per share for Q3 2026. Promis Neurosciences Earnings HeadlinesPromis Neurosciences (NASDAQ:PMN) Stock Price Target Cut by Roth CapitalNovember 4 at 1:48 AM | americanbankingnews.comProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026November 3 at 7:00 AM | globenewswire.comDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start with $150,000 and it's gone in under six years. A new Prudential survey of more than 3,000 Americans over 50 found 86% don't feel free to spend their savings on things they enjoy. Tim Plaehn, who has advised investors since the 1980s, is tracking a monthly income fund built on major U.S. companies that pays cash without requiring investors to sell shares.November 4 at 1:00 AM | Investors Alley (Ad)ProMIS Names Commercial Chief; PMN310 Data Due Q1 2027; Stock DownOctober 6, 2026 | rttnews.comProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial OfficerOctober 6, 2026 | globenewswire.comProMIS Neurosciences to Participate in Upcoming Conferences and Events in SeptemberSeptember 1, 2026 | globenewswire.comSee More Promis Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email. Email Address About Promis NeurosciencesPromis Neurosciences (NASDAQ:PMN) Inc. (NASDAQ: PMN) is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases. The company’s research focuses on misfolded proteins, which can form toxic structures associated with conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and other neurological disorders. ProMIS uses its proprietary target-discovery platform to identify disease-specific toxic protein conformations and develop antibodies intended to selectively bind and neutralize them while avoiding healthy forms of the same proteins. Its lead product candidate, PMN310, is an investigational antibody designed to target toxic soluble amyloid-beta oligomers implicated in Alzheimer’s disease. The company has also pursued programs directed at misfolded proteins associated with other neurodegenerative conditions. ProMIS Neurosciences is based in Toronto, Canada, and conducts research and development activities through North American operations and collaborations. The company was founded to advance antibody-based therapies for diseases that have historically been difficult to treat. Its leadership has included Chief Executive Officer Neil McFarlane and co-founder and Chief Scientific Officer Dr. Neil Cashman, a researcher known for work on protein misfolding and neurodegenerative disease.View Promis Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainMarriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%? Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
